An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

Ardelyx Investigative Site 419, The Bronx

Ardelyx Investigative Site 414, Bethlehem

Ardelyx Investigative Site 415, Bethesda

Ardelyx Investigative Site 426, Raleigh

Ardelyx Investigative Site 411, Charlotte

Ardelyx Investigative Site 412, Wilmington

Ardelyx Investigative Site 420, New Bern

Ardelyx Investigative Site 408, Asheville

Ardelyx Investigative Site 421, Orangeburg

Ardelyx Investigative Site 428, Sumter

Ardelyx Investigative Site 404, Columbia

Ardelyx Investigative Site 430, Miami

Ardelyx Investigative Site 410, Lauderdale Lakes

Ardelyx Investigative Site 429, Huntsville

Ardelyx Investigative Site 418, Nashville

Ardelyx Investigative Site 413, Knoxville

Ardelyx Investigative Site 431, Tupelo

Ardelyx Investigative Site 409, Brookhaven

Ardelyx Investigative Site 417, Columbus

Ardelyx Investigative Site 424, Roseville

Ardelyx Investigative Site 402, Kalamazoo

Ardelyx Investigative Site 423, St Louis

Ardelyx Investigative Site 432, Shreveport

Ardelyx Investigative Site 405, Bellville

Ardelyx Investigative Site 422, San Antonio

Ardelyx Investigative Site 407, San Antonio

Ardelyx Investigative Site 406, Austin

Ardelyx Clinical Site 403, Denver

Ardelyx Investigative Site 427, Meridian

Ardelyx Investigative Site 401, St. George

Ardelyx Investigative Site 416, Albuquerque

Ardelyx Investigative Site 425, Riverside